Create PDF Recommend Print

Neutral Red Uptake

Cor.At® cardiomyocytes provide a standardized, homogenous and reproducible cell system for the in vitro classification of a compound‘s cardio-cytotoxic potential. After incubation with test compounds, end points such as neutral red uptake can be used to determine effects which directly affect the viability and integrity of cardiac cells when compared to a non-specific reference cell type, e.g. mouse fibroblasts.Cor.At® cardiomyocytes can also be used to detect effects of compounds on mitochondrial function and levels of cardiac-specific troponin release.

Cor.At® cardiomyocytes provide a physiologically relevant and predictive in vitro model for cardiac safety screening in early lead optimization. Improving the ability to determine potential cardiotoxic effects of compounds in early stages of drug development reduce costs and improve productivity, providing better measures to move lead compounds towards preclinical and clinical development.

The Cor.At® Tox Assay has been validated in-house using 40 drugs with known cardiac safety profile to predict cardiac specific cytotoxicity of test compounds. The validation study revealed specificity, sensitivity, and positive and negative predictive values of > 90% each. Reference compounds are run within each test to ensure reproducible results.

Advantage Neutral Red Uptake analysis
  • Integrated cell culture model representing primary-like cardiac physiology.
  • Predictive, relevant and robust test system capable of medium to high throughput screening.
  • Various read-outs of cell viability and cytotoxicity possible.
  • Comparison with possible effects on cardiac electrophysiology and mitochondrial function within the same cell system.
  • Early and quick results on cardiac toxicity, time- and cost effective.
  • Either standardized or customized protocols available with respect to drug treatment period, concentrations, and read-out.
  • Library-specific validation studies possible.